CTMX CYTOMX THERAPEUTICS INC. revenue, earnings and financials
For the quarter ended June 30, 2026, CYTOMX THERAPEUTICS INC. reported revenue of $1.42M (down 92.4% from a year earlier), net income of −$20.7M and diluted EPS of n/a; over the last four quarters revenue was $18.3M and net income −$79.7M; for the fiscal year ended December 2025 revenue was $76.2M, down 44.8% on the year before.
CTMX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $76.2M, gross profit n/a, operating income −$22.4M, net income −$17.4M (margin -22.8%), EPS n/a
- Fiscal year ended Dec 2024: revenue $138M, gross profit n/a, operating income $25.0M, net income $31.9M (margin 23.1%), EPS n/a
- Fiscal year ended Dec 2023: revenue $101M, gross profit n/a, operating income −$6.48M, net income −$569K (margin -0.6%), EPS n/a
- Fiscal year ended Dec 2022: revenue $53.2M, gross profit n/a, operating income −$101M, net income −$99.3M (margin -186.8%), EPS n/a
- Fiscal year ended Dec 2021: revenue $37.3M, gross profit n/a, operating income −$116M, net income −$116M (margin -310.5%), EPS n/a
CTMX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $1.42M (down 92.4% year over year), net income −$20.7M, EPS n/a
- Quarter ended Mar 31, 2026: revenue $10.3M (down 79.9% year over year), net income −$18.2M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue $663K (down 98.3% year over year), net income −$26.5M, EPS n/a
- Quarter ended Sep 30, 2025: revenue $5.96M (down 82.2% year over year), net income −$14.2M, EPS n/a
- Quarter ended Jun 30, 2025: revenue $18.7M (down 25.7% year over year), net income −$154K, EPS n/a
- Quarter ended Mar 31, 2025: revenue $50.9M (up 22.8% year over year), net income $23.5M, EPS n/a
- Quarter ended Dec 31, 2024 (from the annual report): revenue $38.1M (up 43.2% year over year), net income $18.9M, EPS n/a
- Quarter ended Sep 30, 2024: revenue $33.4M (up 26.7% year over year), net income $5.74M, EPS n/a
- Quarter ended Jun 30, 2024: revenue $25.1M (up 1.6% year over year), net income −$6.53M, EPS n/a
- Quarter ended Mar 31, 2024: revenue $41.5M (up 76.4% year over year), net income $13.8M, EPS n/a
- Quarter ended Dec 31, 2023 (from the annual report): revenue $26.6M (up 32.2% year over year), net income $837K, EPS n/a
- Quarter ended Sep 30, 2023: revenue $26.4M (up 136.7% year over year), net income $2.99M, EPS n/a
- Quarter ended Jun 30, 2023: revenue $24.7M (up 92.4% year over year), net income −$1.09M, EPS n/a
- Quarter ended Mar 31, 2023: revenue $23.5M (up 159.9% year over year), net income −$3.31M, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue $20.1M (up 80.8% year over year), net income −$8.78M, EPS n/a
- Quarter ended Sep 30, 2022: revenue $11.1M (down 36.6% year over year), net income −$29.1M, EPS n/a
- Quarter ended Jun 30, 2022: revenue $12.9M (down 21.1% year over year), net income −$29.5M, EPS n/a
- Quarter ended Mar 31, 2022: revenue $9.04M (down 43.4% year over year), net income −$32.0M, EPS n/a
- Quarter ended Dec 31, 2021: revenue $11.1M, net income −$34.8M, EPS n/a
- Quarter ended Sep 30, 2021: revenue $17.6M, net income −$31.0M, EPS n/a
CTMX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$75.6M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$86.2M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$56.0M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$111M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$119M, share buybacks n/a
CTMX balance sheet
- Jun 30, 2026: cash $17.2M, total assets $381M, total liabilities $79.2M, shareholders' equity $302M
- Mar 31, 2026: cash $28.8M, total assets $359M, total liabilities $39.4M, shareholders' equity $320M
- Dec 31, 2025: cash $12.7M, total assets $152M, total liabilities $52.6M, shareholders' equity $99.0M
- Sep 30, 2025: cash $34.2M, total assets $158M, total liabilities $50.9M, shareholders' equity $107M
- Jun 30, 2025: cash $49.0M, total assets $175M, total liabilities $55.1M, shareholders' equity $120M
- Mar 31, 2025: cash $47.6M, total assets $98.5M, total liabilities $73.4M, shareholders' equity $25.0M
- Dec 31, 2024: cash $38.1M, total assets $121M, total liabilities $121M, shareholders' equity −$456K
- Sep 30, 2024: cash $40.6M, total assets $139M, total liabilities $162M, shareholders' equity −$23.5M
What is CTMX's revenue?
CYTOMX THERAPEUTICS INC. reported $18.3M of revenue over its last four quarters, through June 30, 2026.
Is CTMX profitable?
No. CYTOMX THERAPEUTICS INC. lost $79.7M over the last four quarters.